



**Press Release – For Immediate Release**

**ResMed Completes Acquisition of BiancaMed**

**ResMed to Expand its Diagnostic Range and Patient Reach through Strategic Acquisition**

**San Diego and Dublin, Ireland, 6<sup>th</sup> July 2011**, ResMed ([NYSE: RMD](#) and [ASX: RMD](#)), a leading developer, manufacturer and distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders, today announced the acquisition of BiancaMed Ltd (“BiancaMed”), a leading Irish medical technology company. ResMed has acquired all of BiancaMed’s shares for cash.

BiancaMed sells an innovative, convenient, non-contact device for the monitoring of sleep and breathing in the home and hospital markets. The core of BiancaMed’s proprietary technology is a sensitive motion sensor that can detect respiration and movement without being connected to the human body.

ResMed is committed to advancing innovative technology in sleep and respiratory medicine and commercialising innovative products incorporating these technologies on a global basis. ResMed, which has a long-standing relationship with BiancaMed having provided seed investment in 2003, is seeking to expand its diagnostic range and patient reach through this strategic acquisition.

BiancaMed, a University College Dublin spin-out company, was co-founded in 2003 by Dr. Philip de Chazal, Dr. Conor Hanley and Professor Conor Heneghan to commercialise research undertaken in UCD’s School of Electrical, Electronic and Mechanical Engineering. BiancaMed is headquartered in NovaUCD, the Innovation and Technology Transfer Centre, and currently employs 29 people.

Announcing the acquisition, Peter Farrell, ResMed’s chairman and chief executive officer said, “We are committed to innovation in sleep and respiratory medicine and the related co-morbidities by commercializing products incorporating novel technologies. We have worked closely with BiancaMed for many years and have been investors since their inception in 2003. BiancaMed has exciting technology and a world-class team. We believe there are many opportunities for BiancaMed’s applications that will provide future growth, and we look forward to maintaining and building the BiancaMed team.”

Through this acquisition ResMed intends to grow and develop the exciting connected health sector in Ireland.

Welcoming this announcement Dr. Conor Hanley, BiancaMed's chief executive officer said, "This acquisition will result in broadening the use of BiancaMed's unique technology and will further build on the momentum achieved by BiancaMed to date. As part of ResMed Inc., we will continue to support our existing customers. The successful completion of this transaction was in large part attributable to the dedication and talent of the BiancaMed team and the invaluable support received from all our investors and shareholders."

BiancaMed's shareholders include Enterprise Ireland, DFJ ePlanet Ventures, Invest Northern Ireland, ResMed, Seventure Partners and University College Dublin.

Dennis Atkinson, Managing Partner of DFJ ePlanet Capital, said, "We are proud of the achievements of the BiancaMed team and believe this acquisition is testament to both the unique and powerful technology and the strength and commitment of the team. ResMed will be an excellent home for the next phase of BiancaMed's growth."

Iain Wilcock, who represented Seventure on BiancaMed's Board, commented, "BiancaMed operates at the interface between the consumer wellness and medical device sectors. We have made an excellent return on our investment and we are sure that Conor and his team will be able to build a substantial business faster with the extra resources that ResMed can provide to the business at this critical stage in its development.

**ENDS**

6<sup>th</sup> July 2011

**For more information contact:** Dr. Conor Hanley, CEO, BiancaMed, t: + 353 1 716 3755 or e: [conor.hanley@biancamed.com](mailto:conor.hanley@biancamed.com) or Micéal Whelan, NovaUCD, t: + 353 1 716 3712 or e: [miceal.whelan@ucd.ie](mailto:miceal.whelan@ucd.ie).

**Editor's Notes**

**ResMed** is a leading developer, manufacturer, and distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. We are dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients

and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing. [www.resmed.com](http://www.resmed.com)

**BiancaMed**, an Irish medical technology company, has developed a contactless, accurate device for the measurement of sleep and breathing. BiancaMed, a University College Dublin (UCD) spin-out company, was co-founded in 2003 by Dr Philip de Chazal, Dr Conor Hanley and Professor Conor Heneghan, to commercialise research undertaken in UCD's School of Electrical, Electronic and Mechanical Engineering.

The core of BiancaMed's proprietary technology is a sensitive motion sensor that can detect respiration and movement without being connected to the human body. The sensor incorporates sophisticated biometric software that converts the motion data into measurements of sleep and breathing.

BiancaMed is headquartered in NovaUCD, the Innovation and Technology Transfer Centre at UCD and currently employs a staff of 29. Shareholders include Enterprise Ireland, DFJ ePlanet Ventures, Invest Northern Ireland, ResMed, Seventure Partners and University College Dublin. [www.biancamed.com](http://www.biancamed.com)